15000-43-8Relevant articles and documents
Remarkably efficient and direct route to quinolines and benzoazepines from the condensation of benzoxazinediones with phosphonium carbanion salts
Abdou, Wafaa M.,Kamel, Azza A.
, p. 3945 - 3960 (2007)
Treatment of 2H-3,1-benzoxazine-2,4(1H)-dione (1a) with vinyltriphenylphosphonium bromide (2a) gives substituted benzoazepine 8a (48% yield) and indolizinone 12 (27% yield), whereas substituted quinolinone 15 and benzoazepine 8b were isolated from the rea
4-HYDROXY-2-QUINOLONES. 18. SYNTHESIS AND ANTITHYROID ACTIVITY OF 1-R-2-OXO-3-(4-OXO-3H-QUINAZOLIN-2-YL)-4-HYDROXYQUINOLINES
Ukrainets, I. V.,Taran, S. G.,Bezuglyi, P. A.,Kovalenko, S. N.,Turov, A. V.,Marusenko, N. A.
, p. 1044 - 1047 (1993)
Preparative methods for the synthesis of 1-R-2-oxo-3-(4-oxo-3H-quinazolin-2-yl)-4-hydroxyquinolines based on ethyl esters or nitriles of 1-R-2-oxo-4-hydroxyquinoline-3-carboxylic acids and anthranilamide or ethyl anthranilate correspondingly were proposed
OXY-CYANOQUINOLINONE PDE9 INHIBITORS
-
Page/Page column 25; 26, (2017/02/24)
The present invention is directed to oxycyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of
AZA-CYANOQUINOLINONE PDE9 INHIBITORS
-
Page/Page column 26, (2017/02/24)
The present invention is directed to azacyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.